Strata Skin Sciences (SSKN) to Release Quarterly Earnings on Thursday

Strata Skin Sciences (NASDAQ:SSKN) is expected to announce its results before the market opens on Thursday, March 26th. Analysts expect Strata Skin Sciences to post earnings of ($0.26) per share and revenue of $5.53 million for the quarter.

Strata Skin Sciences Stock Performance

Shares of Strata Skin Sciences stock traded down $0.04 during trading hours on Wednesday, reaching $0.24. 723 shares of the stock traded hands, compared to its average volume of 470,328. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 10.22. The firm has a market capitalization of $1.42 million, a price-to-earnings ratio of -0.09 and a beta of 0.45. The company has a 50 day moving average price of $0.67 and a 200 day moving average price of $1.26. Strata Skin Sciences has a one year low of $0.12 and a one year high of $3.86.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Strata Skin Sciences in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Strata Skin Sciences stock. Susquehanna International Group LLP purchased a new position in Strata Skin Sciences, Inc. (NASDAQ:SSKN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned 0.24% of Strata Skin Sciences at the end of the most recent reporting period. 32.43% of the stock is currently owned by institutional investors.

Strata Skin Sciences Company Profile

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.